Competitor Analysis: Janus Kinase (JAK) Inhibitors
The present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from preclinical stages up to marketed JAK Inhibitors as of May 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. The database also contains information about discontinued projects. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
As cytokines play pivotal roles in immunity and inflammation, targeting of cytokines and their receptors represents an effective means of treating such diseases. Janus kinases (JAK) are a small family of receptor-associated kinases, that together with signal transducers and activators of transcription (STAT), provide a rapid signalling pathway for cytokines. Four JAKs have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target because of its restricted hematopoietic tissue expression and because of its specific association with the common gamma chain of the interleukin-2 (IL-2) receptor which is shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21.
The report includes a compilation of current active projects in research and development of selective and dual- or multi-kinase inhibitors incl. JAK inhibiton, for the treatment of myelofibrosis, polycythemia vera, psoriasis, rheumatoid arthritis and other inflammatory diseases. In addition, the report lists company-specific pipelines of JAK inhibitors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
As cytokines play pivotal roles in immunity and inflammation, targeting of cytokines and their receptors represents an effective means of treating such diseases. Janus kinases (JAK) are a small family of receptor-associated kinases, that together with signal transducers and activators of transcription (STAT), provide a rapid signalling pathway for cytokines. Four JAKs have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target because of its restricted hematopoietic tissue expression and because of its specific association with the common gamma chain of the interleukin-2 (IL-2) receptor which is shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21.
The report includes a compilation of current active projects in research and development of selective and dual- or multi-kinase inhibitors incl. JAK inhibiton, for the treatment of myelofibrosis, polycythemia vera, psoriasis, rheumatoid arthritis and other inflammatory diseases. In addition, the report lists company-specific pipelines of JAK inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- JAK1 Inhibitors
- JAK2 Inhibitors
- JAK1/2 Inhibitors
- JAK3 Inhibitors
- Tyk2 Inhibitors
- Pan-JAK Inhibitors
- Dual Kinase Inhibitors incl. JAK inhibition
- Multi-Kinase Inhibitors incl. JAK inhibition
- Not Specified JAK Inhibitors
- Corporate R&D Pipelines of JAK Inhibitos
- About La Merie
